Catalyst Pharmaceuticals Valuation Multiples

Catalyst Pharmaceuticals Overview

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.

Founded

2006

HQ

Employees

182

Website

catalystpharma.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $601M

EBITDA: $320M

EV

$3B

Valuation Multiples

Multiples.vc

Start free trial

Catalyst Pharmaceuticals Financials

Catalyst Pharmaceuticals reported last 12-month revenue of $601M and EBITDA of $320M.

In the same LTM period, Catalyst Pharmaceuticals generated $514M in gross profit, $320M in EBITDA, and $232M in net income.

Catalyst Pharmaceuticals P&L

In the most recent fiscal year, Catalyst Pharmaceuticals reported revenue of $589M and EBITDA of $321M.

Catalyst Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals has current market cap of $3B, and enterprise value of $3B.

Catalyst Pharmaceuticals' stock price is $26.26.

Catalyst Pharmaceuticals Valuation Multiples

Catalyst Pharmaceuticals trades at 4.2x EV/Revenue multiple, and 7.8x EV/EBITDA.

Catalyst Pharmaceuticals Financial Valuation Multiples

As of April 18, 2026, Catalyst Pharmaceuticals has market cap of $3B and EV of $3B.

Equity research analysts estimate Catalyst Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Catalyst Pharmaceuticals has a P/E ratio of 13.8x.

Catalyst Pharmaceuticals Margins & Growth Rates

Catalyst Pharmaceuticals' revenue in the last 12 month grew by 8%.

Catalyst Pharmaceuticals' revenue per employee in the last FY averaged $3.2M, while opex per employee averaged $1.3M for the same period.

Catalyst Pharmaceuticals' rule of 40 is 58% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Catalyst Pharmaceuticals' rule of X is 68% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Catalyst Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Catalyst Pharmaceuticals M&A Activity

Catalyst Pharmaceuticals acquired XXX companies to date.

Last acquisition by Catalyst Pharmaceuticals was on XXXXXXXX, XXXXX. Catalyst Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Catalyst Pharmaceuticals Investment Activity

Catalyst Pharmaceuticals invested in XXX companies to date.

Catalyst Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Catalyst Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).